Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has schizophrenia, diagnosed according to DSM-5(TM). (Diagnostic and Statistical Manual of Mental Disorders) and confirmed by the Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders (MINI-Schz).~* The patient is receiving treatment with a psychiatrist in either an inpatient or outpatient facility.~* The patient has been treated with adequate dose(s) of antipsychotic drug treatment for at least 2 weeks prior to the Screening Visit.~* The patient has failed to show an adequate response in the level of psychotic symptoms during at least one documented treatment trial with an adequate dose of an antipsychotic drug prescribed for an adequate time (at least lasting for 6 weeks) within 2 years prior to the Screening Visit. The failure to respond to the current antipsychotic drug treatment trial may be considered a retrospective failed treatment, if the patient has been treated for 6 weeks with adequate dose(s) of antipsychotic drug(s).~* The patient has a PANSS total score of ≥80 (on 1-7 scale) and a score of ≥4 (≥ Moderate on 1-7 scale) on at least 2 of the following PANSS items at the Screening and at Baseline 1 \[Week 0\] Visits: P2 - Conceptual disorganization, P3 - Hallucinatory behavior, P6 - Suspiciousness/persecution, G9 - Unusual thought content; AND the patient has a CGI-S score of ≥4 (≥ Moderately ill) at the Screening and at Baseline 1 (Week 0) Visits.~Exclusion Criteria:~* The patient has any current primary psychiatric disorder other than schizophrenia, as assessed using the MINI-Schz.~* The patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (DSM-5™ criteria).~* The patient is experiencing an acute exacerbation of his/her psychotic symptoms.~* The patient has been treated with, AND is resistant to, clozapine according to the investigator's judgement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prospective Confirmation (PC) Period (Type: EXPERIMENTAL): Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
- Double-blind treatment (DBT) period, Lu AF35700 10 mg (Type: EXPERIMENTAL): Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
- DBT Period, Continued treatment from PC Period (Type: EXPERIMENTAL): Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period

Based on this trial design, predict the completion outcome and termination type (if applicable).